<?xml version="1.0" encoding="UTF-8"?>
<p>In the second session, Tom Polasek, PhD, Certara/Royal Adelaide Hospital, Monash University, made a presentation titled “Virtual Twins Based on PBPK Models for Precision Dosing in Drug Development and Beyond,” which described the potential use of the PBPK model approach not only in drug developments but also in clinical settings. Ping Zhao, PhD, of the Bill and Melinda Gates Foundation, made a presentation titled “Physiologically Based Pharmacokinetic model analysis for drug development and regulatory decision making: Past, Present, and Future,” which covered the current reliability of PBPK model analysis and challenges for the future as well as further challenges for utilization of PBPK model analysis. Shinichi Kijima, MSc, PMDA, explained the current situation of PBPK model analysis for regulatory purpose in Japan and offered an overview of progress on development of guideline for PBPK model analysis at the AMED research group. The workshop became a first opportunity to present the scope or purpose of the guideline named “Guidelines for Analysis Report Involving Physiologically based Pharmacokinetic Modeling (draft)” as well as the table of contents of the guideline (
 <bold>Table</bold>
 <xref rid="psp412554-tbl-0001" ref-type="table">
  <bold>1</bold>
 </xref>).
</p>
